drugset / Trial / NCT05637216

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216

Phase 2 Active not recruiting 43 enrolled Shaw Cancer Center Steadman Philippon Research Institute · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.

Timeline

Start
2023-08-17
Primary completion
2027-08-17
Completion
2027-08-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 25 mg Oral